Process for Preparation of Erlotinib and its Pharmaceutically Acceptable Salts

ABSTRACT

A process for the preparation of a salt of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine comprising reacting a 4-halo-6,7-bis(2-methoxyethoxy)quinazoline with 3-aminophenyl acetylene or an acid salt thereof under acidic conditions to form the corresponding acid salt of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine, the process optionally further comprising converting the acid salt of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine to N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of and claims priority to U.S. patent application Ser. No. 12/593,212 filed on Dec. 7, 2009, published as U.S. Publication No. 2010/0094004 A1, which is a filing under 35 U.S.C. 371 of International Application No. PCT/GB2008/001186 filed Apr. 3, 2008, entitled “Process for Preparation of Erlotinib and Its Pharmaceutically Acceptable Salts,” claiming priority of Indian Patent Application No. 681/MUM/2007 filed Apr. 4, 2007, which applications are incorporated by reference herein in their entirety.

FIELD OF THE INVENTION

The present invention relates to an improved process for the synthesis of erlotinib and its pharmaceutically acceptable salts.

BACKGROUND OF THE INVENTION

Erlotinib is a Human Epidermal Growth Factor Receptor Type 1/Epidermal Growth Factor Receptor (HER1/EGFR) tyrosine kinase inhibitor.

Erlotinib is described chemically as N-(3-ethynylphenyl)-6,7-bis (2-methoxyethoxy)quinazolin-4-amine, and its hydrochloride salt is represented by the compound of Formula I.

Erlotinib is disclosed in EP0817775 which also a discloses process for its preparation, which involves adding 3-ethynylaniline and 4-chloro-6,7-bis(2-methoxyethoxy)quinazoline in isopropanol containing pyridine and then refluxing the mixture for 4 hours under the atmosphere of dry nitrogen. The solvent is removed and residue is extracted in 10% methanol in CHCl₃ and saturated aqueous NaHCO₃. N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine base is separated chromatographically and converted to the hydrochloride salt in a solvent such as CHCl₃ using hydrochloric acid.

EP1044969 claims a method for preparing intermediates and compounds covering erlotinib. This patent discloses a process for preparing N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine which involves stifling 4-[3-[[6,7-bis(2-methoxyethoxy)-4-quinazolinyl]amino]phenyl1-2-methyl-3-butyn-2-ol with anhydrous sodium hydroxide and 2-methoxyethanol and heating at reflux for 47 hours. The reaction mixture is cooled to 20-25° C. and concentrated HCl is added to it. The resulting mixture is granulated at 20-25° C. to crystallize the product.

Indian patent application 902/CHE/2006 discloses a process for preparation of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine hydrochloride. The process involves reacting 3,4-dihydroxy benzaldehyde with substituted ethylmethyl ether in the presence of an inert solvent and base to obtain 3,4-bis(2-methoxyethoxy)benzaldehyde. This 3,4-bis(2-methoxyethoxy)benzaldehyde is converted to 3,4-bis(2-methoxyethoxy)benzaldoxime in the presence of a base and organic solvent and is further dehydrated to 3,4-bis(2-methoxyethoxy)benzonitrile. The benzonitrile so obtained is nitrated to obtain 4,5-bis(2-methoxyethoxy)-2-nitrobenzonitrile which is further reduced to obtain 2-amino-4,5-bis(2-methoxyethoxy)benzonitrile. N′-(3-ethynylphenyl)-N,N-dimethyl formamidine obtained on formylation of 3-ethynylamine with N,N-dimethyl formamidine is coupled with 2-amino-4,5-bis(2-methoxyethoxy)benzonitrile to obtain erlotinib free base which on treatment with a polar solvent containing hydrochloric acid gives erlotinib hydrochloride.

Indian patent application 904/CHE/2006 also discloses a process for preparation of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine hydrochloride. The process involves reacting 3,4-dihydroxy benzaldehyde with substituted ethylmethyl ether in the presence of an inert solvent and base to obtain 3,4-bis(2-methoxyethoxy)benzaldehyde. This 3,4-bis(2-methoxyethoxy)benzaldehyde is converted to 3,4-bis(2-methoxyethoxy)benzaldoxime in the presence of a base and organic solvent and is further dehydrated to 3,4-bis(2-methoxyethoxy)benzonitrile. The benzonitrile so obtained is nitrated to obtain 4,5-bis(2-methoxyethoxy)-2-nitrobenzonitrile which is further reduced to get 2-amino-4,5-bis(2-methoxyethoxy)benzonitrile. 2-amino-4,5-bis(2-methoxyethoxy)benzonitrile is formylated with a formylating agent in the presence of formic acid derivative to obtain N′-[2-cyano-4,5-bis(2-methoxyethoxy)phenyl]-N,N-dimethylformamidine which is coupled with an aniline derivative to obtain erlotinib free base which on treatment with a polar solvent containing hydrochloric acid gives erlotinib hydrochloride.

The processes described in the prior art require anhydrous conditions and are carried out under an inert atmosphere. These processes are time consuming and cumbersome. Also a large variety of solvents are required for extraction and purification. Hence, there is a need for the development of a simple and industrially economical process.

OBJECT OF THE INVENTION

The object of the present invention is to provide an improved process for the synthesis of erlotinib and its pharmaceutically acceptable salts.

SUMMARY OF THE INVENTION

The present invention discloses an improved process for the synthesis of erlotinib and its pharmaceutically acceptable salts which process is simple and economical for commercial production.

According to a first aspect of the present invention, there is provided a process for the preparation of a salt of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine comprising reacting a 4-halo-6,7-bis(2-methoxyethoxy)quinazoline with 3-aminophenyl acetylene or an acid salt thereof under acidic conditions to form the corresponding acid salt of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine, the process optionally further comprising converting the acid salt of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine to N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine.

In an embodiment, the acidic conditions are obtained by using an acid selected from the group consisting of a mineral acid, an organic acid or mixtures thereof. The acid may be selected from the group consisting of hydrochloric acid, hydrobromic acid, sulphuric acid, p-toluene sulphonic acid, benzoic acid, citric acid, succinic acid, oxalic acid, benzene sulphonic acid, tartaric acid, methane sulphonic acid, phosphoric acid and mixtures thereof. Preferably, the acid used is hydrochloric acid.

In an embodiment, the 4-halo-6,7-bis(2-methoxyethoxy)quinazoline is selected from 4-chloro-6,7-bis(2-methoxyethoxy)quinazoline, 4-bromo-6,7-bis(2-methoxyethoxy)quinazoline or 4-iodo-6,7-bis(2-methoxyethoxy)quinazoline. Preferably, the 4-halo-6,7-bis(2-methoxyethoxy)quinazoline is 4-chloro-6,7-bis(2-methoxyethoxy)quinazoline.

In an embodiment, the 3-aminophenyl acetylene is not in the form of a salt. In an alternative embodiment, the acid salt of 3-aminophenyl acetylene is the hydrochloride salt.

Typically, 4-chloro-6,7-bis(2-methoxyethoxy)quinazoline is reacted with 3-aminophenyl acetylene.

In an embodiment, the process is carried out in the presence of a solvent selected from the group consisting of water, C₁-C₄ alcohols, ketones, hydrocarbons or mixtures thereof. The solvent may be selected from the group consisting of water, dimethyl carbonate, special denatured spirit (SPDS), acetonitrile, acetone, isopropyl alcohol and mixtures thereof. The solvent may also be tetrahydrofuran, toluene or ethyl acetate. In an embodiment, the solvent is a mixture of solvents. For example, the mixture may be of acetonitrile and toluene, ethyl acetate and acetonitrile or acetone and water.

Following reaction of the 4-halo-6,7-bis(2-methoxyethoxy)quinazoline with the 3-aminophenyl acetylene or salt thereof, the acid salt of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine may be converted to N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine. For example, the reaction mixture comprising the acid salt of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine may be basified in the presence of a base to obtain N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine. The base may be selected from the group consisting of an organic base and an inorganic base. The base may be an alkali metal hydroxide or an alkali metal carbonate. In an embodiment, the base is selected from the group consisting of sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, ammonia, pyridine and triethyl amine.

The process may be carried out a temperature below about 40° C. For example the process may be carried out a temperature ranging from about 20° C. to about 40° C., suitably from about 20° C. to about 35° C., preferably from about 25° C. to about 30° C.

In an embodiment, when the acid is added to the starting materials, the temperature may be from about 20° C. to about 35° C., preferably from 25° C. to 30° C. This temperature may be maintained during reaction or may be increased to around 35° C. to about 40° C.

The process may further comprise converting the N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine to a second salt. The salt may be the hydrochloride salt. Alternatively, the second salt may be the sulphate, oxalate, tosylate, phosphate, benzoate, citrate, succinate, benzene sulphonate, hydrobromide, tartrate or mesylate salt. The conversion may be carried out in any manner well known to the skilled person, for example by reacting the N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine with the corresponding acid. Thus, the sulphate, oxalate, tosylate, phosphate, benzoate, citrate, succinate, benzene sulphonate, hydrobromide, tartrate or mesylate salts may be prepared by reacting the N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine with sulphuric acid, oxalic acid, p-toluene sulphonic acid, phosphoric acid, benzoic acid, citric acid, succinic acid, benzene sulphonic acid, hydrobromic acid, tartaric acid or methane sulphonic acid, respectively.

In an embodiment, the N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine is converted to the hydrochloride salt using hydrochloric acid or hydrogen chloride gas in an organic solvent.

In an embodiment, the process is not carried out under an inert atmosphere. The process of the present invention may advantageously be carried out under atmospheric conditions. By “atmospheric conditions” is meant not under an inert atmosphere, at a temperature ranging from about 23° C. to about 27° C. and under atmospheric pressure.

According to another aspect of the present invention, there is provided erlotinib or a salt thereof prepared according to the process described above.

According to yet another aspect of the present invention, there is provided a pharmaceutical composition comprising erlotinib or a salt thereof prepared according to the process described above together with one or more pharmaceutically acceptable excipients. Suitable excipients are well known to those skilled in the art.

DETAILED DESCRIPTION

The first aspect of the present invention provides an improved process for preparation of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine and its pharmaceutically acceptable salts. The process of the present invention is economical and commercially advantageous over the processes of the prior art.

Generally the reaction of the amine and chloro compound is carried out in the presence of a base which promotes the reaction to completion. However, surprisingly it has been found that the reaction of the present invention can be carried out in the presence of an acid which forms another aspect of the invention wherein N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine is prepared by reacting a 4-halo-6,7-bis(2-methoxyethoxy)quinazoline with 3-aminophenyl acetylene or an acid salt thereof under acidic conditions.

In one embodiment, the present invention provides a process which is carried out by reacting 4-chloro-6,7-bis(2-methoxyethoxy)quinazoline with 3-aminophenyl acetylene under acidic conditions.

Yet another aspect of the present invention provides the preparation of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine by reacting a 4-halo-6,7-bis(2-methoxyethoxy)quinazoline with 3-aminophenyl acetylene or a salt thereof at a temperature below 40° C.

Further, the present invention provides preparation of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine by reacting a 4-halo-6,7-bis(2-methoxyethoxy)quinazoline with 3-aminophenyl acetylene or a salt thereof in a suitable solvent.

In the process of the present invention, the acidic conditions may be obtained by using an acid selected from the group consisting of a mineral acid, an organic acid or mixtures thereof. The acid may be selected from the group consisting of hydrochloric acid, hydrobromic acid, sulphuric acid, p-toluene sulphonic acid, benzoic acid, citric acid, succinic acid, oxalic acid, benzene sulphonic acid, tartaric acid, methane sulphonic acid, phosphoric acid and mixtures thereof. Preferably the acid used is hydrochloric acid. The acid salt of erlotinib corresponds to the acidic conditions used, for example the use of hydrochloric acid will result in formation of the hydrochloride salt of erlotinib.

The acid salt of erlotinib may be isolated and not converted to erlotinib base, or may be converted to erlotinib base.

In an embodiment, the acid salt is purified before isolation, for example purified using a suitable solvent and dried. The solvent used for purification is preferably selected from C₁-C₄ alcohols, more preferably methanol.

In an alternate embodiment of the invention, the pharmaceutically acceptable salt of erlotinib is isolated. The salt may then be suspended in a suitable solvent and basified using a suitable base to obtain erlotinib. The base used may be selected from the group consisting of organic and inorganic bases. The base may be selected from the group consisting of sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, ammonia, pyridine, triethyl amine. The so-obtained erlotinib may then be further converted to a second salt such as its hydrochloride salt, for example using hydrochloric acid or hydrogen chloride gas in a suitable organic solvent. Other second salts of erlotinib include the sulphate, oxalate, tosylate, phosphate, benzoate or mesylate salts.

One of the advantages of this reaction is that it does not require any heating as prior art processes require. For example, the process described in EP0817775 involves adding 3-ethynylaniline and 4-chloro-6,7-bis-(2-methoxy-ethoxy)quinazoline to isopropanol containing pyridine and refluxing the mixture. In an embodiment, the process of the present invention is carried out at a temperature below the reflux temperature of the solvent used.

Furthermore, the reaction proceeds faster under the conditions of the present invention. The acid catalyses the reaction and also aids in formation of the salt. The presence of an acid catalyst increases the rate of reaction and leads to completion of reaction without the formation of any major impurities.

The reaction is carried out in a suitable solvent which may be selected from the group consisting of water, C₁-C₄ alcohols, ketones, hydrocarbons or mixture thereof. The solvent used may be selected from the group consisting of water, dimethyl carbonate, special denatured spirit (SPDS), acetonitrile, acetone, isopropyl alcohol and mixtures thereof.

A further advantage is that the reaction may be carried out under atmospheric conditions and it does not require any inert reaction conditions as required in the process disclosed in EP0817775. The prior art reactions are complicated and very lengthy while the reaction of the present invention requires less time and is easy to carry out.

In an embodiment, the process of the present invention can be represented as shown in the following reaction scheme:

EXAMPLES

The present invention is now further illustrated by the following examples, which do not, in any way, limit the scope of the invention.

Example-1a Preparation of Erlotinib Hydrochloride:

5.0 g of 4-chloro-6,7-bis(2-methoxyethoxy)quinazoline was suspended in 75 ml water and 2.55 g of 3-aminophenyl acetylene was charged at 25-30° C. Further 1.0 ml 50% hydrochloric acid was added. The reaction mass was stirred at 25-30° C. for 2 hours. The solid obtained was filtered and washed with water. The product was dried at 40 -45° C. to obtain 6.1 g of erlotinib hydrochloride.

In a similar manner, different solvents were used for preparing erlotinib hydrochloride under acidic conditions as given in table 1 below:

TABLE 1 HPLC Example no. Solvent used Efficiency Purity Reaction Time 1a Water 88.76% 99.12%   2 hours 1b Dimethyl carbonate 77.50% 98.50% 1.5 hours 1c Denatured spirit 87.31% 99.03% ½ hour 1d Acetonitrile 91.67% 97.44% ½ hour 1e Isopropanol 90.22% 98.87% ½ hour 1f Acetone 90.22% 98.40% ½ hour

Example-2a Preparation of Erlotinib Hydrochloride:

5.0 g of 4-chloro-6,7-bis(2-methoxyethoxy)quinazoline was suspended in 75 ml of water and 2.55 g of 3-aminophenyl acetylene was added at 25-30° C. followed by 1.0 ml of 50% hydrochloric acid. The reaction mass was heated at 35-40° C. for 1 hour. The solid obtained was filtered and washed with water. The product was dried at 40-45° C. to obtain 5.8 g of erlotinib hydrochloride.

In a similar manner, different solvents were used for preparing erlotinib hydrochloride under acidic conditions as given in table 2 below:

TABLE 2 Example no. Solvent used Efficiency HPLC Purity Reaction time 2a Water 85.40% 99.22% 1 hour 2b Denatured spirit 96.04% 99.25% 1 hour 2c Tetrahydrofuran 93.13% 98.89% 1 hour 2d Acetone 87.31% 98.81% 1 hour 2e Acetonitrile 96.33% 99.23% 1 hour 2f Acetonitrile + 93.42% 99.02% 1 hour Toluene 2g Ethyl acetate + 96.04% 83.74% 1 hour Acetonitrile 2h Acetone + water 72.75% 99.01% 1 hour

Example-3 Preparation of Erlotinib Hydrochloride:

5 g of 4-chloro-6,7-bis(2-methoxyethoxy)quinazoline was suspended in 150 ml denatured spirit (SPDS) and 4.6 g of 3-aminophenyl acetylene was charged at 25-30° C. Further 1.0 ml of methane sulphonic acid was added. The reaction mass was stirred at 25-30° C. for 3 hours. Solid obtained was filtered, washed with SPDS and dried under vacuum. This solid was suspended in water, basified with ammonia and stirred for 10 minutes. The resulting erlotinib base was isolated, washed with water and dried under vacuum. The base was suspended in water and acidified to pH 1.0-2.0 using hydrochloric acid. The reaction mixture was stirred for 2 hours, filtered, washed with water and dried at 40-45° C. to obtain 5.8 g of erlotinib hydrochloride.

Example-4 Preparation of Erlotinib Hydrochloride:

10.0 g of 4-chloro-6,7-bis(2-methoxyethoxy)quinazoline was suspended in 300 ml methanol and 9.2 g of 3-aminophenyl acetylene was charged at 25-30° C. Further 2.0 ml of benzoic acid was added. The reaction mass was stirred at 25-30° C. for 4 hours. Solid obtained was filtered, washed with methanol and dried under vacuum. This solid was suspended in water and then basified with sodium hydroxide and stirred for 10 minutes. The resulting erlotinib base was isolated, washed with water and dried under vacuum. The base was suspended in water and acidified to pH 1.0-2.0 using hydrochloric acid. The reaction mixture was stirred for 2 hours, filtered, washed with water and dried to obtain 11.2 g of erlotinib hydrochloride.

Example-5 Preparation of Erlotinib Hydrochloride:

15.0 g of 4-chloro-6,7-bis(2-methoxyethoxy)quinazoline was suspended in 450 ml ethanol and 13.8 g of 3-aminophenyl acetylene was added at 25-30° C. Further 3.0 g tartaric acid was added. The reaction mass was stirred at 25-30° C. for 6 hours. Solid obtained was filtered, washed with water and dried under vacuum. This solid was suspended in water, basified with potassium hydroxide and stirred for 10 minutes. The resulting erlotinib base was isolated by filtration, washed with ethanol and dried under vacuum. The solid obtained was then suspended in water and acidified to pH 1.0-2.0 using hydrochloric acid. The reaction mixture was stirred for 2 hours, filtered, washed with water and dried at 40-45° C. to obtain 18.3 g of erlotinib hydrochloride.

Example-6 Preparation of Erlotinib Hydrochloride:

50 g of 4-chloro-6,7-bis(2-methoxyethoxy)quinazoline was suspended in 1500 ml acetonitrile and 46 g of 3-aminophenyl acetylene was added at 25-30° C., followed by 10 ml acetic acid. The reaction mass was stirred at 25-30° C. for 30 minutes. Solid obtained was filtered, washed with water and dried under vacuum. This solid was suspended in water, basified with potassium hydroxide and stirred for 10 minutes. The resulting erlotinib base was isolated, washed with acetonitrile and dried under vacuum. The solid obtained was then suspended in water and acidified to pH 1.0-2.0 using hydrochloric acid. The reaction mixture was stirred for 2 hours, filtered, washed with water and dried at 40-45° C. to obtain 63 g of erlotinib hydrochloride.

Example 7 Preparation of Erlotinib Sulphate:

1.98 Kg of 4-chloro-6,7-bis(2-methoxyethoxy)quinazoline was suspended in 30 litres of water and 1.0 Kg of 3-aminophenyl acetylene was charged at 25-30° C. Further 0.4 litres sulphuric acid was added. The reaction mass was heated and stirred at 35-40° C. for 1 hour. The solid obtained was filtered and washed with ethyl acetate. The product was dried at 38-40° C. to obtain 2.65 Kg of erlotinib sulphate.

Example 8 Preparation of Erlotinib Tosylate:

5.0 g of 4-chloro-6,7-bis(2-methoxyethoxy)quinazoline was suspended in 75 ml ethyl acetate and 2.55 g of 3-aminophenyl acetylene was charged at 25-30° C. 0.9 g of p-toluyl sulphonic acid was added. The reaction mass was heated and stirred at 35-40° C. for 2 hours. The solid obtained was filtered and washed with ethyl acetate. The product was dried at 38-40° C. to obtain 6.6 g of erlotinib tosylate.

Example 9 Preparation of Erlotinib Oxalate:

1.98 g of 4-chloro-6,7-bis(2-methoxyethoxy)quinazoline was suspended in 30 litres of acetone and 1.0 Kg of 3-aminophenyl acetylene was charged at 25-30° C. 0.7 Kg of oxalic acid was added. The reaction mass was heated and stirred at 35-40° C. for 2 hours. The solid obtained was filtered and washed with acetone. The product was dried at 38-40° C. to obtain 2.67 Kg of erlotinib oxalate.

Example 10 Preparation of Erlotinib Hydrochloride:

1.98 Kg of 4-chloro-6,7-bis(2-methoxyethoxy)quinazoline was suspended in 30 litres of acetonitrile and 10 litres of toluene and 1.0 Kg of 3-aminophenyl acetylene was charged at 25-30° C. and hydrochloric acid was added. The reaction mass was heated and stirred at 35-40° C. for 6 hours. The solid obtained was filtered and washed with a mixture of acetonitrile and toluene. The product was dried at 38-40° C. to obtain 2.5 Kg of erlotinib hydrochloride.

It will be appreciated that the invention may be modified within the scope of the appended claims. 

1. A sulphate salt, an oxalate salt, or a tosylate salt, or a succinate salt of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine prepared by a process comprising reacting a 4halo-6,7-bis(2-methoxyethoxy)quinazoline with 3-aminophenyl acetylene or an acid salt thereof under acidic conditions to form the corresponding acid salt of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin4-amine.
 2. The sulphate salt of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine of claim 1, wherein the acidic conditions are obtained using sulphuric acid.
 3. The oxalate salt of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine of claim 1, wherein the acidic conditions are obtained using, oxalic acid.
 4. The tosylate salt of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin4-amine of claim 1, wherein the acidic conditions are obtained using p-toluene sulphonic acid.
 5. The succinate salt of N-(3-ethynylphenyl)-6,7-bis(2.-methoxyethoxy)quinazolin4-amine of claim 1, wherein the acidic conditions are obtained using succinic acid.
 6. The sulphate salt, the oxalate salt, the tosylate salt, or the succinate salt of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine of claim 1, wherein the process further comprises converting the acid salt of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine to N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine.
 7. The sulphate salt, the oxalate salt, the tosylate salt, or the succinate salt of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine of claim 1, wherein the process further comprises basifying the acid salt of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine in the presence of a base to obtain N-(3-ethynylphenyl)-6,7-bis-methoxyethoxy)quinazolin-4-amine.
 8. The sulphate salt, the oxalate ash, the tosylate salt, or the succinate salt of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine of claim 1, wherein the process further comprises converting the N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine to the sulphate salt, the oxalate salt, the tosylate salt, or the succinate salt of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine.
 9. The sulphate salt, the oxalate salt, the tosylate salt, or the succinate salt of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin of claim 1, wherein the process is not carried out under an inert atmosphere.
 10. The sulphate salt the oxalate salt, the tosylate salt, or the succinate salt of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine of claim 1, wherein the process is carried out at a temperature below 40° C.
 11. The sulphate salt, the oxalate salt, the tosylate salt, or the succinate salt of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine of claim 1, wherein the process is carried out in the presence of a solvent selected from the group consisting of water, C₁-C₄ alcohols, ketones, hydrocarbons or mixtures thereof.
 12. The sulphate salt of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxyl)quinazolin-4-amine of claim
 1. 13. The oxalate salt of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine of claim
 1. 14. The tosylate salt of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine of claim
 1. 15. The succinate salt of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine of claim
 1. 16. A sulphate salt, an oxalate salt, a tosylate salt, or a succinate salt of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine.
 17. The sulphate salt of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine of claim
 16. 18. The oxalate salt of 3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine of claim
 16. 19. The tosylate salt of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine of claim
 16. 20. The succinate salt of N-(3-ethynylphenyl)-6,7-bis(-methoxyethoxy)quinazolin-4-amine of claim
 16. 